Stavudine effects on rat pregnancy outcome

Journal of Obstetrics and Gynaecology Research

Volumn 30, Issue 3, 2004, Pages 242-245

  Braga Barreto, Regina Lúcia ^a,d   De Jesus Simões, Manuel ^b   Mahmed Amed, Abes ^b   Soares Júnior, José Maria ^b   Oliveira Filho, Ricardo Martins ^c   Kulay Jr , Luiz ^b  

^a UNIVERSIDADE DO OESTE PAULISTA UNOESTE   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Departamento de Tocoginecologia   (Brazil)

Author keywords

Antiretroviral drugs; Fetal resorption; Pregnancy; Rat; Stavudine

Indexed keywords

STAVUDINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; FETUS RESORPTION; FETUS WEIGHT; NIDATION; NONHUMAN; PLACENTA WEIGHT; RAT; STATISTICAL ANALYSIS; STEREOMICROSCOPY; WEIGHT GAIN;

ANIMALS; FEMALE; FETUS; HIV INFECTIONS; ORGAN SIZE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; RANDOM ALLOCATION; RATS; RATS, WISTAR; REPRODUCTION; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE;

EID: 3042840994     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2004.00180.x     Document Type: Article

References (30)

1. Will GF. Eurasia and the epidemic. Newsweek 2002; 140: 80.
2. Bicego G, Rutstein S, Johnson K. Dimensions of the emerging orphan crisis in sub-Saharan Africa. Soc Sci Med 2003; 56: 1235-1247.
3. Brettle RP, Leen CLS. The natural history of HIV and AIDS in women. AIDS 1991; 5: 1283-1292.
4. Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-1180.
5. Tuntland T, Odinecs A, Pereira CM, Nosbisch C, Unadkat JD. In vitro models to predict the in vivo mechanism, rate and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus. Am J Obstet Gynecol 1999; 180: 198-206.
6. Katz A. The evolving art of caring for pregnant women with HIV infection. J Obstet Gynecol Neonatal Nurs 2003; 32: 102-108.
7. Gastaut JA. The problems in France created by the HIV/AIDS epidemic at the onset of the third millennium. Presse Med 2003; 32: 268-275.
8. Volberding PA. HIV therapy in 2003: consensus and controversy. AIDS 2003; 17(Suppl. 1): S4-S11.
9. Lea AP, Faulds D. Stavudine. A review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996; 51: 846-864.
10. Balzarini J, Egberink H, Hartmann K et al. Antiretrovirus specificity and intracellular metabolism of 2′, 3′-didehydro-2′-3′- dideoxythymidine (stavudine) and its 5-monophasphate triester prodrug So324. Mol Pharmacol 1996; 50: 1207-1213.
11. Huang P, Farquhar D, Plunkett W. Selective action of 2′,3′- didehydro-2′,3′-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases. J Biol Chem 1992; 267: 2817-2822.
12. Schilling BE, Nelson DR, Proctor JE, Diamond SS, Kaul S, Hawkins HC. The nonclinical toxicologic profile of D4T. Curr Ther Res 1995; 56: 201-218.
13. Lee LM, Henderson DK. Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. Drug Saf 2001; 24: 587-597.
14. Cheer SM, Goa KL. Stavudine once daily. Drugs 2002; 62: 2667-2674.
15. Scarsella A, Coodley G, Shalit P et al. Stavudine-associated peripheral neuropathy in zidovudine-naive patients: effect of stavudine exposure and antiretroviral experience. Adv Ther 2002; 19: 1-8.
16. Battillocchi B, Diana M, Dandolo R, Stefanini S, D'Amore L, Negro P. Drug-induced acute pancreatitis: a personal contribution. Chir Ital 2002; 54: 605-612.
17. Cornejo-Juarez P, Sierra-Madero J, Volkow-Fernandez P. Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment. Arch Med Res 2003; 34: 64-69.
18. Mandelbrot L, Kermarrec N, Marcollet A et al. Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS 2003; 17: 272-273.
19. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002; 78: 58-59.
20. Forstenlehner M. AIDS: New FDA approved agents. Pharm Unserer Zeit 2000; 29: 58.
21. Kaul S, Dandekar KA, Schilling BE, Barbhaiya RH. Toxicokinetics of 2′,3′-didehydro-3-deoxythymidine stavudine (D4T). Drug Metab Dispos 1999; 27: 1-12.
22. Hamilton JB, Wolff JM. The effect of male hormone substance upon birth and prenatal development in the rat. Anat Rec 1938; 70: 433-440.
23. von Giesen HJ, Arendt G. Drug treatment for HIV-1-associated dementia. Curr Opin Invest Drugs 2002; 3: 1643-1646.
24. Gogu SR, Beckman BS, Agrawal KC. Anti-HIV drugs: comparative toxicities in murine fetal liver and bone marrow erythroid progenitor cells. Life Sci 1989; 45: iii-vii.
25. Toltzis P, Mourton T, Magnuson T. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J Infect Dis 1994; 169: 1100-1102.
26. Levacher M, Bouscarat F, Landman R et al. Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavir. AIDS Res Hum Retroviruses 2000; 16: 1869-1875.
27. Trabattoni D, Lo Caputo S, Biasin M et al. Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. Clin Diagn Laboratory Immunol 2002; 9: 1114-1118.
28. Austin KJ, Bany BM, Belden EL, Rempel LA, Cross JC, Hansen TR. Interferon-stimulated gene-15 (Isg15) expression is up-regulated in the mouse uterus in response to the implanting conceptus. Endocrinology 2003; 144: 3107-3113.
29. Scialli AR. A Clinical Guide to Reproductive and Developmetal Toxicology Boca Raton, FL: CRC Press, 1992.
30. Fujinaga M, Schulte M, Holodniy M. Assessment of developmental toxicity of antiretroviral drugs using a rat whole embryo culture system. Teratology 2000; 62: 108-114.